NasdaqGM - Nasdaq Real Time Price • USD
CureVac N.V. (CVAC)
As of 11:35 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 9 | 7 |
| Avg. Estimate | -0.22 | -0.22 | -0.95 | -0.72 |
| Low Estimate | -0.33 | -0.31 | -1.4 | -1.28 |
| High Estimate | -0.14 | -0.14 | -0.53 | -0.18 |
| Year Ago EPS | -0.3 | -0.33 | -1.26 | -0.95 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 10 | 8 |
| Avg. Estimate | 16.05M | 16.05M | 73.16M | 91.28M |
| Low Estimate | 8.58M | 8.58M | -- | 15.17M |
| High Estimate | 25.67M | 25.67M | 174.33M | 258.1M |
| Year Ago Sales | 14.46M | 8M | 57.49M | 73.16M |
| Sales Growth (year/est) | 11.00% | 100.70% | 27.20% | 24.80% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.37 | -0.26 | -0.25 | -0.2 |
| EPS Actual | -0.3 | -0.33 | -0.24 | -0.42 |
| Difference | 0.07 | -0.07 | 0.01 | -0.22 |
| Surprise % | 18.90% | -26.90% | 4.00% | -110.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.22 | -0.22 | -0.95 | -0.72 |
| 7 Days Ago | -0.18 | -0.19 | -0.97 | -0.77 |
| 30 Days Ago | -0.18 | -0.19 | -0.98 | -0.78 |
| 60 Days Ago | -0.18 | -0.19 | -0.95 | -0.84 |
| 90 Days Ago | -0.18 | -0.19 | -0.95 | -0.79 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | 1 |
| Up Last 30 Days | 2 | 1 | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | CVAC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 26.70% | -- | -- | 6.50% |
| Next Qtr. | 33.30% | -- | -- | 12.00% |
| Current Year | 24.60% | -- | -- | 5.30% |
| Next Year | 24.20% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -10.76% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Guggenheim: Buy | 4/26/2021 |
| Downgrade | Credit Suisse: Neutral to Underperform | 12/10/2020 |
| Initiated | B of A Securities: Buy | 9/8/2020 |
| Initiated | Jefferies: Hold | 9/8/2020 |
| Initiated | Credit Suisse: Neutral | 9/8/2020 |
Related Tickers
BNTX BioNTech SE
89.39
+2.49%
VIR Vir Biotechnology, Inc.
8.28
+0.61%
NVAX Novavax, Inc.
4.2250
+3.30%
ARCT Arcturus Therapeutics Holdings Inc.
26.78
+0.87%
DAWN Day One Biopharmaceuticals, Inc.
15.98
+7.10%
SAGE Sage Therapeutics, Inc.
14.55
+6.28%
BMRN BioMarin Pharmaceutical Inc.
81.97
+1.30%
SLRN Acelyrin, Inc.
4.3100
+1.65%
VXRT Vaxart, Inc.
0.7171
+1.03%
VERV Verve Therapeutics, Inc.
6.30
+2.27%